Abstract:Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer type that urgently requires effective therapeutic strategies. Andrographolide, a labdane diterpenoid compound abundant in Andrographis paniculata, has anticancer effects against various cancer types, but its anticancer activity and mechanism against PDAC remain largely uncharacterized. Purpose: This study explores novel drug target(s) and underlying molecular mechanism of andrographolide against PDAC. Study design and methods: The malignant phenotypes of PDAC cells, PANC-1 and MIA PaCa-2 cells, were measured using MTT, clonogenic assays, and Transwell migration assays. A PDAC xenograft animal model was used to evaluate tumor growth in vivo. Western blot, immunofluorescence and immunohistochemistry were used for measuring protein expression. The TCGA database was analyzed to evaluate promoter methylation status, gene expression, and their relationship with patient survival rates. RT-qPCR was used for detecting mRNA expression. Reporter assays were used for detecting signal transduction pathways. Promoter DNA methylation was determined by sodium bisulfite treatment and methylation-specific PCR (MSP). The biological function and role of specific genes involved in drug effects were measured through gene overexpression. Results: Andrographolide treatment suppressed the proliferation and migration of PDAC cells and impaired tumor growth in vivo. Furthermore, andrographolide induced the mRNA and protein expression of zinc finger protein 382 (ZNF382) in PDAC cells. Overexpression of ZNF382 inhibited malignant phenotypes and cancer-associated signaling pathways (AP-1, NF-κB and β-catenin) and oncogenes (ZEB-1, STAT-3, STAT-5, and HIF-1α). Overexpression of ZNF382 delayed growth of PANC-1 cells in vivo. ZNF382 mRNA and protein expression was lower in tumor tissues than in adjacent normal tissues of pancreatic cancer patients. Analysis of the TCGA database found the ZNF382 promoter is hypermethylated in primary pancreatic tumors which correlates with its low expression. Furthermore, andrographolide inhibited the expression of DNA methyltransferase 3 beta (DNMT3B) and increased the demethylation of the ZNF382 promoter in PDAC cells. Overexpression of DNMT3B attenuated the andrographolide-suppressed proliferation and migration of PDAC cells. Conclusion: Our finding revealed that ZNF382 acts as a tumor suppressor gene in pancreatic cancer and andrographolide restores ZNF382 expression to suppress pancreatic cancer, providing a novel molecular target and a promising therapeutic approach for treating pancreatic cancer.

A Quantitative Chemical Proteomics Approach to Profile the Specific Cellular Targets of Andrographolide, a Promising Anticancer Agent That Suppresses Tumor Metastasis*

A Proteomic Landscape of Pharmacologic Perturbations for Functional Relevance

Andrographolide Inhibits Breast Cancer Through Suppressing COX-2 Expression and Angiogenesis Via Inactivation of P300 Signaling and VEGF Pathway.

Chemical Proteomic Strategies for the Discovery and Development of Anticancer Drugs

An Ion-Current-based, Comprehensive and Reproducible Proteomic Strategy for Comparative Characterization of the Cellular Responses to Novel Anti-Cancer Agents in a Prostate Cell Model.

Targeting signaling pathways with andrographolide in cancer therapy (Review)

Andrographolide Against Lung Cancer-New Pharmacological Insights Based on High-Throughput Metabolomics Analysis Combined with Network Pharmacology

A network-based pharmacological investigation to identify the mechanistic regulatory pathway of andrographolide against colorectal cancer

Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer

Investigation of Targets and Anticancer Mechanisms of Covalently Acting Natural Products by Functional Proteomics.

The Prowess of Andrographolide As a Natural Weapon in the War Against Cancer

The therapeutic potential of andrographolide in cancer treatment

Andrographolide inhibits melanoma tumor growth by inactivating the TLR4/NF-κB signaling pathway

Identification of Poly(adp-Ribose)polymerase 1 and 2 (PARP1/2) As Targets of Andrographolide Using an Integrated Chemical Biology Approach.

Target identification of natural and traditional medicines with quantitative chemical proteomics approaches.

Mechanism of andrographis paniculata on lung cancer by network pharmacology and molecular docking

Target Profiling of an Anticancer Drug Curcumin by an In Situ Chemical Proteomics Approach

Hunting Molecular Targets for Anticancer Reagents by Chemical Proteomics

Current Evidence on Molecular Mechanisms of Andrographolide in Cancer

A Quantitative Method for Screening and Identifying Molecular Targets for Nanomedicine.

Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor suppressor gene ZNF382